Swedish Orphan Biovitrum Beheer

Beheer criteriumcontroles 3/4

De CEO Swedish Orphan Biovitrum is Guido Oelkers, benoemd in May2017, heeft een ambtstermijn van 7.5 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 48.88M, bestaande uit 25.1% salaris en 74.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde SEK 138.98M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 4 jaar.

Belangrijke informatie

Guido Oelkers

Algemeen directeur

SEK 48.9m

Totale compensatie

Percentage CEO-salaris	25.1%
Dienstverband CEO	7.5yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26

Analyse CEO-vergoeding

Hoe is Guido Oelkers's beloning veranderd ten opzichte van Swedish Orphan Biovitrum's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	SEK 4b
Jun 30 2024	n/a	n/a	SEK 2b
Mar 31 2024	n/a	n/a	SEK 2b
Dec 31 2023	SEK 49m	SEK 12m	SEK 2b
Sep 30 2023	n/a	n/a	SEK 3b
Jun 30 2023	n/a	n/a	SEK 3b
Mar 31 2023	n/a	n/a	SEK 3b
Dec 31 2022	SEK 47m	SEK 11m	SEK 3b
Sep 30 2022	n/a	n/a	SEK 2b
Jun 30 2022	n/a	n/a	SEK 3b
Mar 31 2022	n/a	n/a	SEK 3b
Dec 31 2021	SEK 42m	SEK 10m	SEK 3b
Sep 30 2021	n/a	n/a	SEK 3b
Jun 30 2021	n/a	n/a	SEK 3b
Mar 31 2021	n/a	n/a	SEK 3b
Dec 31 2020	SEK 33m	SEK 10m	SEK 3b
Sep 30 2020	n/a	n/a	SEK 3b
Jun 30 2020	n/a	n/a	SEK 3b
Mar 31 2020	n/a	n/a	SEK 4b
Dec 31 2019	SEK 33m	SEK 10m	SEK 3b
Sep 30 2019	n/a	n/a	SEK 3b
Jun 30 2019	n/a	n/a	SEK 3b
Mar 31 2019	n/a	n/a	SEK 3b
Dec 31 2018	SEK 26m	SEK 9m	SEK 2b
Sep 30 2018	n/a	n/a	SEK 2b
Jun 30 2018	n/a	n/a	SEK 2b
Mar 31 2018	n/a	n/a	SEK 1b
Dec 31 2017	SEK 16m	SEK 5m	SEK 1b

Compensatie versus markt: De totale vergoeding ($USD 4.52M ) Guido } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 2.61M ).

Compensatie versus inkomsten: De vergoeding van Guido is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Guido Oelkers (59 yo)

7.5yrs

Tenure

SEK 48,883,000

Compensatie

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Guido Oelkers	CEO & President	7.5yrs	SEK 48.88m	0.12% SEK 138.3m
Henrik Stenqvist	Chief Financial Officer	6.3yrs	geen gegevens	0.016% SEK 18.2m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.8yrs	geen gegevens	0.0089% SEK 9.9m
Daniel Rankin	Head of Strategy & Corporate Development	2.8yrs	geen gegevens	0.0029% SEK 3.2m
Lena Bjurner	Head of Human Resources	1.8yrs	geen gegevens	geen gegevens
Armin Reininger	Senior Scientific & Medical Advisor	7.8yrs	geen gegevens	0.0047% SEK 5.2m
Norbert Oppitz	Head of International	7.1yrs	geen gegevens	0.012% SEK 12.9m
Sofiane Fahmy	Head of Europe	5.8yrs	geen gegevens	0.0077% SEK 8.6m
Duane Barnes	Head of North America	3.8yrs	geen gegevens	geen gegevens
Mahmood Ladha	Head of Strategic Transformation Operations	no data	geen gegevens	0.0018% SEK 2.0m
Christine Wesstrom	Head of Technical Operations	2.7yrs	geen gegevens	0.0032% SEK 3.6m
Lydia Abad-Franch	Senior VP	1.8yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SOBI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hans Wigzell	Chairman of Scientific Advisory Board	23.8yrs	SEK 158.00k	geen gegevens
Helena Saxon	Director	13.6yrs	SEK 828.00k	0.0067% SEK 7.4m
Anders Ullman	Director	1.5yrs	SEK 463.00k	0.0010% SEK 1.1m
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ralf Pettersson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stefan Del Prato	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Annette Clancy	Independent Chairman	10.5yrs	SEK 770.00k	0.00099% SEK 1.1m
Staffan Schuberg	Independent Director	4.5yrs	SEK 827.00k	0.0021% SEK 2.3m
Filippa Stenberg	Director	3.5yrs	SEK 673.00k	0.00017% SEK 189.0k
Katy Mazibuko	Employee Representative Director	1.8yrs	geen gegevens	0.0013% SEK 1.4m
Christophe Bourdon	Independent Director	1.5yrs	SEK 433.00k	geen gegevens

4.0yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SOBI wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Swedish Orphan Biovitrum Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

CEO & President recently sold kr29m worth of stock

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Recent updates

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

Investor sentiment improves as stock rises 15%

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

CEO & President recently sold kr29m worth of stock

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 21%

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Independent Director recently bought kr439k worth of stock

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well